Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 540

1.

Mammalian tumor xenografts induce neovascularization in zebrafish embryos.

Nicoli S, Ribatti D, Cotelli F, Presta M.

Cancer Res. 2007 Apr 1;67(7):2927-31.

2.

The zebrafish/tumor xenograft angiogenesis assay.

Nicoli S, Presta M.

Nat Protoc. 2007;2(11):2918-23.

PMID:
18007628
3.

Fibroblast growth factor 2-induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay.

Nicoli S, De Sena G, Presta M.

J Cell Mol Med. 2009 Aug;13(8B):2061-8. doi: 10.1111/j.1582-4934.2008.00432.x. Epub 2008 Jul 24.

4.

SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.

Zhang S, Cao Z, Tian H, Shen G, Ma Y, Xie H, Liu Y, Zhao C, Deng S, Yang Y, Zheng R, Li W, Zhang N, Liu S, Wang W, Dai L, Shi S, Cheng L, Pan Y, Feng S, Zhao X, Deng H, Yang S, Wei Y.

Clin Cancer Res. 2011 Jul 1;17(13):4439-50. doi: 10.1158/1078-0432.CCR-10-3109. Epub 2011 May 27.

5.

Zebrafish embryo, a tool to study tumor angiogenesis.

Tobia C, De Sena G, Presta M.

Int J Dev Biol. 2011;55(4-5):505-9. doi: 10.1387/ijdb.103238ct. Review.

6.

Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.

Liao F, Doody JF, Overholser J, Finnerty B, Bassi R, Wu Y, Dejana E, Kussie P, Bohlen P, Hicklin DJ.

Cancer Res. 2002 May 1;62(9):2567-75.

7.

A novel xenograft model in zebrafish for high-resolution investigating dynamics of neovascularization in tumors.

Zhao C, Wang X, Zhao Y, Li Z, Lin S, Wei Y, Yang H.

PLoS One. 2011;6(7):e21768. doi: 10.1371/journal.pone.0021768. Epub 2011 Jul 13.

8.

Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.

Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.

9.

Resveratrol derivative, trans-3,5,4'-trimethoxystilbene, exerts antiangiogenic and vascular-disrupting effects in zebrafish through the downregulation of VEGFR2 and cell-cycle modulation.

Alex D, Leong EC, Zhang ZJ, Yan GT, Cheng SH, Leong CW, Li ZH, Lam KH, Chan SW, Lee SM.

J Cell Biochem. 2010 Feb 1;109(2):339-46. doi: 10.1002/jcb.22405.

PMID:
20014068
10.

Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation.

Tammela T, Zarkada G, Wallgard E, Murtomäki A, Suchting S, Wirzenius M, Waltari M, Hellström M, Schomber T, Peltonen R, Freitas C, Duarte A, Isoniemi H, Laakkonen P, Christofori G, Ylä-Herttuala S, Shibuya M, Pytowski B, Eichmann A, Betsholtz C, Alitalo K.

Nature. 2008 Jul 31;454(7204):656-60. doi: 10.1038/nature07083. Epub 2008 Jun 25.

PMID:
18594512
11.

Effect of proton beam on blood vessel formation in early developing zebrafish (Danio rerio) embryos.

Jang GH, Ha JH, Huh TL, Lee YM.

Arch Pharm Res. 2008 Jun;31(6):779-85. doi: 10.1007/s12272-001-1226-1. Epub 2008 Jun 19.

PMID:
18563361
12.

TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model.

Ohta M, Kawabata T, Yamamoto M, Tanaka T, Kikuchi H, Hiramatsu Y, Kamiya K, Baba M, Konno H.

Surg Today. 2009;39(12):1046-53. doi: 10.1007/s00595-009-4020-y. Epub 2009 Dec 8.

PMID:
19997799
13.

Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model.

Lee SL, Rouhi P, Dahl Jensen L, Zhang D, Ji H, Hauptmann G, Ingham P, Cao Y.

Proc Natl Acad Sci U S A. 2009 Nov 17;106(46):19485-90. doi: 10.1073/pnas.0909228106. Epub 2009 Nov 3.

14.

Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.

Jung MH, Lee SH, Ahn EM, Lee YM.

Carcinogenesis. 2009 Apr;30(4):655-61. doi: 10.1093/carcin/bgp039. Epub 2009 Feb 18.

PMID:
19228635
15.

LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice.

Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D, Chen YF, Iversen P, Teicher BA.

Cancer Chemother Pharmacol. 2004 Feb;53(2):133-40. Epub 2003 Oct 31.

PMID:
14593497
16.

AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.

Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L, Bready J, Estrada J, Cattley R, Kaufman S, Chen D, Gan Y, Kumar G, Meyer J, Neervannan S, Alva G, Talvenheimo J, Montestruque S, Tasker A, Patel V, Radinsky R, Kendall R.

Cancer Res. 2006 Sep 1;66(17):8715-21.

17.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

18.

Engineered human tumor xenografts with functional human vascular networks.

Alonso-Camino V, Santos-Valle P, Ispizua MC, Sanz L, Alvarez-Vallina L.

Microvasc Res. 2011 Jan;81(1):18-25. doi: 10.1016/j.mvr.2010.10.002. Epub 2010 Oct 8.

PMID:
20934439
19.

Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.

Zhang GM, Zhang YM, Fu SB, Liu XH, Fu X, Yu Y, Zhang ZY.

Chin Med J (Engl). 2008 Nov 20;121(22):2324-30.

PMID:
19080341
20.

Antitumor activities of synthetic and natural stilbenes through antiangiogenic action.

Kimura Y, Sumiyoshi M, Baba K.

Cancer Sci. 2008 Oct;99(10):2083-96. doi: 10.1111/j.1349-7006.2008.00948.x.

Supplemental Content

Support Center